DiogenX

Marseille, France

DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.

$36.8M raised

May 2023

Series A

Top Investors

Eli LillyOmnes CapitalBoehringer Ingelheim Venture FundAdBio partnersSunstone Life Science Ventures

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has DiogenX raised?

DiogenX has raised $36.8M in total funding. The most recent round was Series A. The last funding was announced in May 2023.

Who are DiogenX's investors?

DiogenX's investors include Eli Lilly, Omnes Capital, Boehringer Ingelheim Venture Fund, AdBio partners, Sunstone Life Science Ventures.

Where is DiogenX headquartered?

DiogenX is headquartered in Marseille, France.

What does DiogenX do?

DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.

What stage is DiogenX at?

DiogenX is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 10, 2023.

MLA

"DiogenX — Funding & Investors." VCBacked, May 10, 2023, https://www.vcbacked.co/company/diogenx. Accessed June 15, 2026.

APA

VCBacked. (2023). DiogenX — Funding & Investors. Retrieved June 15, 2026, from https://www.vcbacked.co/company/diogenx

Wikipedia (cite web)

{{cite web |title=DiogenX — Funding & Investors |url=https://www.vcbacked.co/company/diogenx |website=VCBacked |access-date=June 15, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 10, 2023.